title: IFNα induces prolonged remissions modeling curative immunologic responses in chronic myeloid leukemia.
abstract: Tyrosine kinase inhibitor therapy has dramatically changed the outcome of chronic myeloid leukemia (CML) patients. However, the treatment is not considered to be curative and may present deleterious side effects, such that additional therapy options are warranted. Here, we discuss the beneficial immunomodulatory effects of interferon α (IFNα) therapy and the immunological changes related to optimal treatment responses.
authors: Hematology Research Unit; Department of Hematology; University of Helsinki and Helsinki University Central Hospital Cancer Center; Helsinki, Finland.
authors: Mette
authors: M
authors: Ilander
authors: Hematology Research Unit; Department of Hematology; University of Helsinki and Helsinki University Central Hospital Cancer Center; Helsinki, Finland.
authors: Anna
authors: A
authors: Kreutzman
authors: Hematology Research Unit; Department of Hematology; University of Helsinki and Helsinki University Central Hospital Cancer Center; Helsinki, Finland.
authors: Satu
authors: S
authors: Mustjoki
keywords: NK-cells; T-cells; chronic myeloid leukemia; curative treatment; immunomodulation; immunosurveillance; interferon-alpha